A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
← catalyst calendarNCT07116616 · readout in 1,398 d
Sponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
166estimated
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-30 | actual | When the study began enrolling |
| Primary completion | 2030-06-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-06-17 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed or Refractory Multiple Myeloma
Intervention
- Drug: mRNA-2808
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Dose-limiting Toxicity
measured Up to 28 days
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
measured Up to 15 months
Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed